Compare SGC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | NTHI |
|---|---|---|
| Founded | 1920 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.2M | 178.4M |
| IPO Year | 1994 | N/A |
| Metric | SGC | NTHI |
|---|---|---|
| Price | $11.56 | $5.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.00 | $15.00 |
| AVG Volume (30 Days) | 25.9K | ★ 88.3K |
| Earning Date | 05-04-2026 | 05-19-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $200.25 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $3.20 |
| 52 Week High | $13.78 | $12.99 |
| Indicator | SGC | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 50.18 |
| Support Level | $9.79 | $4.43 |
| Resistance Level | $13.01 | $5.70 |
| Average True Range (ATR) | 0.46 | 0.72 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 38.60 | 54.88 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).